Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? Rothenberg ML, Berlin JD (2003) J Clin Oncol 21: 3716-7 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) J Clin Oncol 21: 2059-69 Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH (1997) Blood 90: 935-43 Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C, El-Rifai W (2005) Cancer Res 65: 6583-92 Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ (2016) Cancer Res 76: 6657-6668 Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB (1993) Cancer Res 53: 4164-8 Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal. Frøhlich RF, Veigaard C, Andersen FF, McClendon AK, Gentry AC, Andersen AH, Osheroff N, Stevnsner T, Knudsen BR (2007) Nucleic Acids Res 35: 6170-80 Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ (2014) Clin Cancer Res 20: 1190-203 Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19: 1920-5 A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA (2013) Clin Cancer Res 19: 258-67 Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF (2001) Clin Cancer Res 7: 68-73 Prospects and challenges for the development of new therapies for Ewing sarcoma. Grohar PJ, Helman LJ (2013) Pharmacol Ther 137: 216-24 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL (2001) Ann Oncol 12: 1575-80 Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK (2017) Oncotarget 8: 43733-43751 Biological characterization of MLN944: a potent DNA binding agent. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA (2004) Mol Cancer Ther 3: 47-58 Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA (2008) Cancer 113: 186-92 Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA (2004) Cancer 100: 2347-54 Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Cancer 110: 980-8 Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W (2008) Cancer 112: 1688-98 Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H (2003) J Biol Chem 278: 21767-73 Cell cycle-dependent regulation of a human DNA helicase that localizes in DNA damage foci. Gu J, Xia X, Yan P, Liu H, Podust VN, Reynolds AB, Fanning E (2004) Mol Biol Cell 15: 3320-32 Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy. Hariri G, Edwards AD, Merrill TB, Greenbaum JM, van der Ende AE, Harth E (2014) Mol Pharm 11: 265-75 Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Lucumi A, Robledo S, Gama V, Saravia NG (1998) Antimicrob Agents Chemother 42: 1990-5 A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B (2005) Radiother Oncol 76: 54-8 Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP (2006) Ann Surg Oncol 13: 1284-92 Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Invest New Drugs 30: 290-8 Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA (2004) Ann Thorac Surg 78: 1152-60; discussion 1152-60 Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Choy H, Chakravarthy A, Devore RF, Jagasia M, Hande KR, Roberts JR, Johnson DH, Yunus F (2000) Oncology (Williston Park) 14: 43-6 Second-line therapy in colorectal cancer. Berlin J (2000) Oncology (Williston Park) 14: 21-6 Targeting vascular endothelial growth factor in colorectal cancer. Berlin JD (2002) Oncology (Williston Park) 16: 13-5 Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J (2003) Oncology (Williston Park) 17: 20-2 Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA (2013) Head Neck 35: 942-8 Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA (2012) Cancer Chemother Pharmacol 70: 699-705 Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC (2013) Eur J Clin Pharmacol 69: 2073-81 Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML (2006) Am J Clin Oncol 29: 109-15 A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD (2008) Am J Clin Oncol 31: 413-6 Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN (2003) J Gastrointest Surg 7: 1082-8 Diflomotecan. Ipsen. Osheroff N (2004) IDrugs 7: 257-63 Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N (2012) Oncol Rep 28: 1301-8 A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J (2011) Clin Lung Cancer 12: 161-5
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.